Supplementary Table S9 from TPP-45142—an Anti-HER2 T-cell Engager—Designed for Selective HER2-Low Cancer Immunotherapy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Supplementary Table S9 comprises of statistical results for comparison of all groups with the vehicle group (daily)
Fields of Study & Subjects
HER2/EGFR in Cancer Research
Monoclonal and Polyclonal Antibodies Research
Cancer Immunotherapy and Biomarkers
Publication details
- Publication date
- 2 April 2026
- Language
- EN